Dosage Forms. Intranasal Spray: 0.2 mL (available as trivalent product containing two strains of influenza A virus and one influenza B virus strain and as a quadrivalent product containing two strains of influenza A virus and two influenza B virus strains)
Common FDA Label Indication, Dosing, and Titration.
1. Prevention of influenza infection: Adults, healthy, aged 18-49 y, one spray annually; Children, healthy, aged 2-18 y, one spray annually
Off-Label Uses. None
Drug Characteristics: Influenza Virus Vaccine, Live
Medication Safety Issues: Influenza Virus Vaccine, Live
Drug Interactions: Influenza Virus Vaccine, Live
Adverse Reactions: Influenza Virus Vaccine, Live
Efficacy Monitoring Parameters. Prevention of influenza infection.
Toxicity Monitoring Parameters. Syncope, nasal discharge.
Key Patient Counseling Points. Annual seasonal immunization is recommended.
Clinical Pearls. Use current year vaccine only (virus strains and vaccine vary year to year). Transmission of the vaccine virus to susceptible individuals without serious consequences has been documented. Avoid administering to contacts of individuals so severely immunocompromised that they require protective isolation. Vaccine dosing does not need to be repeated if the individual sneezes following administration. Protective antibodies achieved approximately 3 wk after activation and persist for 6 mo.